These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 17078964)

  • 21. Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1.
    Moore PL; Crooks ET; Porter L; Zhu P; Cayanan CS; Grise H; Corcoran P; Zwick MB; Franti M; Morris L; Roux KH; Burton DR; Binley JM
    J Virol; 2006 Mar; 80(5):2515-28. PubMed ID: 16474158
    [TBL] [Abstract][Full Text] [Related]  

  • 22. B cell epitope mapping of human immunodeficiency virus envelope glycoproteins with long (19- to 36-residue) synthetic peptides.
    Neurath AR; Strick N; Lee ES
    J Gen Virol; 1990 Jan; 71 ( Pt 1)():85-95. PubMed ID: 1689372
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discrete partitioning of HIV-1 Env forms revealed by viral capture.
    Stieh DJ; King DF; Klein K; Aldon Y; McKay PF; Shattock RJ
    Retrovirology; 2015 Sep; 12():81. PubMed ID: 26399966
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human antibody responses to HIV type 1 glycoprotein 41 cloned in phage display libraries suggest three major epitopes are recognized and give evidence for conserved antibody motifs in antigen binding.
    Binley JM; Ditzel HJ; Barbas CF; Sullivan N; Sodroski J; Parren PW; Burton DR
    AIDS Res Hum Retroviruses; 1996 Jul; 12(10):911-24. PubMed ID: 8798976
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies.
    Williams WB; Liao HX; Moody MA; Kepler TB; Alam SM; Gao F; Wiehe K; Trama AM; Jones K; Zhang R; Song H; Marshall DJ; Whitesides JF; Sawatzki K; Hua A; Liu P; Tay MZ; Seaton KE; Shen X; Foulger A; Lloyd KE; Parks R; Pollara J; Ferrari G; Yu JS; Vandergrift N; Montefiori DC; Sobieszczyk ME; Hammer S; Karuna S; Gilbert P; Grove D; Grunenberg N; McElrath MJ; Mascola JR; Koup RA; Corey L; Nabel GJ; Morgan C; Churchyard G; Maenza J; Keefer M; Graham BS; Baden LR; Tomaras GD; Haynes BF
    Science; 2015 Aug; 349(6249):aab1253. PubMed ID: 26229114
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibody neutralization escape mediated by point mutations in the intracytoplasmic tail of human immunodeficiency virus type 1 gp41.
    Kalia V; Sarkar S; Gupta P; Montelaro RC
    J Virol; 2005 Feb; 79(4):2097-107. PubMed ID: 15681412
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of a trimeric MPER containing HIV-1 gp41 antigen.
    Hinz A; Schoehn G; Quendler H; Hulsik DL; Stiegler G; Katinger H; Seaman MS; Montefiori D; Weissenhorn W
    Virology; 2009 Aug; 390(2):221-7. PubMed ID: 19539967
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A human monoclonal antibody to HIV-1 gp41 with neutralizing activity against diverse laboratory isolates.
    Cotropia J; Ugen KE; Kliks S; Broliden K; Broliden PA; Hoxie JA; Srikantan V; Williams WV; Weiner DB
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Jul; 12(3):221-32. PubMed ID: 8673526
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-human immunodeficiency virus type 1 human monoclonal antibodies that bind discontinuous epitopes in the viral glycoproteins can identify mimotopes from recombinant phage peptide display libraries.
    Boots LJ; McKenna PM; Arnold BA; Keller PM; Gorny MK; Zolla-Pazner S; Robinson JE; Conley AJ
    AIDS Res Hum Retroviruses; 1997 Dec; 13(18):1549-59. PubMed ID: 9430247
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
    Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
    Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Broadly cross-reactive HIV neutralizing human monoclonal antibody Fab selected by sequential antigen panning of a phage display library.
    Zhang MY; Shu Y; Phogat S; Xiao X; Cham F; Bouma P; Choudhary A; Feng YR; Sanz I; Rybak S; Broder CC; Quinnan GV; Evans T; Dimitrov DS
    J Immunol Methods; 2003 Dec; 283(1-2):17-25. PubMed ID: 14659896
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Generation of HIV-1 Virus-Like Particles expressing different HIV-1 glycoproteins.
    Visciano ML; Diomede L; Tagliamonte M; Tornesello ML; Asti V; Bomsel M; Buonaguro FM; Lopalco L; Buonaguro L
    Vaccine; 2011 Jul; 29(31):4903-12. PubMed ID: 21596074
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction of HIVMN neutralizing antibodies in primates using a prime-boost regimen of hybrid synthetic gp120 envelope peptides.
    Haynes BF; Torres JV; Langlois AJ; Bolognesi DP; Gardner MB; Palker TJ; Scearce RM; Jones DM; Moody MA; McDanal C
    J Immunol; 1993 Aug; 151(3):1646-53. PubMed ID: 8335949
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antigenic properties of a transport-competent influenza HA/HIV Env chimeric protein.
    Ye L; Sun Y; Lin J; Bu Z; Wu Q; Jiang S; Steinhauer DA; Compans RW; Yang C
    Virology; 2006 Aug; 352(1):74-85. PubMed ID: 16725170
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 (HXB2-Env:Ala 582(-->Thr)) decreases viral neutralization by monoclonal antibodies to the CD4-binding site.
    Klasse PJ; McKeating JA; Schutten M; Reitz MS; Robert-Guroff M
    Virology; 1993 Sep; 196(1):332-7. PubMed ID: 8356803
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-gp41 antibodies cloned from HIV-infected patients with broadly neutralizing serologic activity.
    Pietzsch J; Scheid JF; Mouquet H; Seaman MS; Broder CC; Nussenzweig MC
    J Virol; 2010 May; 84(10):5032-42. PubMed ID: 20219932
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improved breadth and potency of an HIV-1-neutralizing human single-chain antibody by random mutagenesis and sequential antigen panning.
    Zhang MY; Shu Y; Rudolph D; Prabakaran P; Labrijn AF; Zwick MB; Lal RB; Dimitrov DS
    J Mol Biol; 2004 Jan; 335(1):209-19. PubMed ID: 14659751
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human monoclonal antibodies to the human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein gp41 enhance HIV-1 infection in vitro.
    Robinson WE; Kawamura T; Gorny MK; Lake D; Xu JY; Matsumoto Y; Sugano T; Masuho Y; Mitchell WM; Hersh E
    Proc Natl Acad Sci U S A; 1990 Apr; 87(8):3185-9. PubMed ID: 2326277
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cross-reactive HIV-1-neutralizing activity of serum IgG from a rabbit immunized with gp41 fused to IgG1 Fc: possible role of the prolonged half-life of the immunogen.
    Zhang MY; Wang Y; Mankowski MK; Ptak RG; Dimitrov DS
    Vaccine; 2009 Feb; 27(6):857-63. PubMed ID: 19084043
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neutralization of diverse HIV-1 strains by monoclonal antibodies raised against a gp41 synthetic peptide.
    Dalgleish AG; Chanh TC; Kennedy RC; Kanda P; Clapham PR; Weiss RA
    Virology; 1988 Jul; 165(1):209-15. PubMed ID: 2838959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.